Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer

Aveo Pharmaceuticals Inc AVEO will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

• The trial is evaluating Fotivda (tivozanib) to Bayer AG's BAYRY Nexavar (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies.
• "This marks the first presentation of five-year follow-up data for patients being treated in the third- or fourth-line RCC setting and helps guide clinical treatment," said Michael Bailey, President, and CEO.
• Landmark five-year follow-up data show PFS rates are consistently higher with Fotivda vs. sorafenib, with 12% vs. 2% and 8% vs. 0% at three and four years, respectively. 
• Long-term PFS represents a clinically meaningful outcome for patients in the third- and fourth-line treatment setting.
• Long-term overall survival was also analyzed, and a non-significant trend favoring Fotivda continued to emerge with the accumulation of events (HR, 0.89).
• Price Action: AVEO shares are up 0.57% at $3.52 during the premarket session on the last check Tuesday.